NCT03294694: Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

NCT03294694
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable symptomatic brain metastases that require treatment
https://ClinicalTrials.gov/show/NCT03294694

Comments are closed.

Up ↑